Market growth and expansion execution
Entering new countries and regions can create delays, organizational strain, and lost revenue.
- Scope
- New market entry and sales expansion
- Materiality
- high
SenzaGen
SenzaGen is a Swedish life science company focused on nonanimal testing for chemical safety and product efficacy. Its core offering combines proprietary GARD® testing methods, consulting services, and laboratory work delivered through its own facilities in Sweden and Italy, supported by a network of partners.
| % | |
|---|---|
| Regulatory toxicology testing | 60% Nonanimal tests used to assess skin and respiratory sensitization and chemical safety. |
| Efficacy testing | 20% Human-relevant preclinical testing using tissue models and organoids for product performance. |
| Consulting and regulatory support | 10% Scientific and regulatory guidance that helps customers select and interpret tests. |
| Partner and license-based testing | 10% Testing capacity and market access delivered through distributors and license partners. |
SenzaGen sells primarily to large multinational companies that need testing during product development, reformulation,...
- Large multinational direct-sales customersprimary
Buy GARD® and related lab services directly for recurring regulatory and development testing.
- Cosmetics and personal care companiesprimary
Use skin sensitization and efficacy testing when launching or reformulating products.
- Chemical and industrial companiesprimary
Buy toxicology testing to support product safety and regulatory compliance.
- Medical device customerssecondary
Use sensitization testing to support ISO and regulatory requirements.
- Distributor and license partner channelsecondary
Partners extend market reach and provide flexible testing capacity.
SenzaGen is headquartered in Lund, Sweden and operates GLP-approved laboratories in Sweden and Italy...
- •Headquartered in Lund, Sweden
- •GLP-approved laboratories in Sweden and Italy
- •Primary commercial focus on Europe
- •Selective sales targeting in the United States
- •Partner network supports expansion into new countries
SenzaGen’s strategy is built around expanding adoption of GARD® through regulatory approvals, technology upgrades, and...
01
Broaden regulatory acceptance of GARD®medium-term
Regulatory approvals increase customer adoption and support repeat testing demand.
02
Scale direct sales to multinational customersshort-term
Large recurring customers fit the lab-based model and improve repeat order visibility.
03
Expand through partners and new marketsmedium-term
Distributors and licensees extend reach without requiring full local infrastructure.
04
Launch new nonanimal test methodslong-term
A broader portfolio increases addressable markets and reduces reliance on one assay family.
SenzaGen faces execution risk in market expansion, product development, and reliance on partners that help scale sales...
Distributor and license partner dependence
A small but important share of revenue and capacity depends on third-party partners fulfilling obligations.
- Scope
- Partner sales and flexible testing capacity
- Materiality
- high
Product development and regulatory adoption
New tests need validation and acceptance before they can generate meaningful revenue.
- Scope
- New assay launches and standards inclusion
- Materiality
- high
Financing needs
Growth initiatives may require additional funding if market penetration is slower than planned.
- Scope
- Capital raises and liquidity planning
- Materiality
- high
Patent and IP protection
Commercial value depends on patents and proprietary methods remaining defensible.
- Scope
- GARD® platform and related methods
- Materiality
- medium
IFRS 16
IFRS 16 leases
Right-of-use assets, lease liabilities, depreciation, and interest expense
Revenue recognition for testing services
Quarterly revenue volatility and contract asset/liability balances
Goodwill and intangible assets
Potential non-cash impairment charges
IFRS first-time adoption
Comparability between 2024 K3 and IFRS figures
: 11/08/2026